Drug intelligence / Profile preview

dTAGv1

Development stage
Discontinued
Lead developer
Bio-Techne
Modality
Small Molecules
Administration
Intraperitoneal, Parenteral
01

Overview

dTAGv1 is a heterobifunctional small molecule degrader used in the degradation TAG (dTAG) system to induce the rapid and specific degradation of proteins fused to a mutant FKBP12 (F36V) tag. Developed by the Bradner lab at the Dana-Farber Cancer Institute, dTAGv1 acts as a molecular bridge between the FKBP12(F36V)-tagged target protein and the Cereblon (CRBN) E3 ubiquitin ligase complex, leading to polyubiquitination and subsequent proteasomal degradation of the fusion protein. This system is primarily used as a research tool for functional genomics and target validation, allowing for acute protein depletion to study immediate biological effects, such as identifying transcriptional targets of oncogenic drivers like NSD2 in multiple myeloma.

Other names
dTAG-1dTAG1dTAG 1
02

Targets

VHL (Von Hippel–Lindau tumor suppressor protein)FKBP1A F36V (Peptidyl-prolyl cis-trans isomerase FKBP1A (FKBP12) engineered domain)FKBP1AFKBP12(F36V)-POI (FK506-binding protein 12 F36V-tagged protein of interest)

Beyond the preview

Go deeper on dTAGv1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dTAGv1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call